Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × Ontruzant × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

OTHER 3 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 205 Carboplatin 116 Gemcitabine 105 Nivolumab 103 Paclitaxel 100 Cisplatin 83 Bevacizumab 82 Cyclophosphamide 76 Dexamethasone 62 Injections 59 Docetaxel 58 Pemetrexed 56 Capecitabine 55 Rituximab 53 atezolizumab 52 Fluorouracil 52 Cetuximab 51 130-nm albumin-bound paclitaxel 51 Oxaliplatin 46 Leucovorin 42 Lenalidomide 39 Ipilimumab 38 venetoclax 37 Azacitidine 35 fludarabine 32 Trastuzumab 32 Fulvestrant 32 Prednisone 31 Irinotecan 31 Albumin-Bound Paclitaxel 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06686394 2026-02-13

MK-1022-009

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡